Other
Carboplatin
0
Pipeline Programs↗
10
Active Trials↗
14
Companies Involved↗
Carboplatin is an early-stage landscape with 0 programs across 14 companies. The most active players are Pfizer, AstraZeneca, Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
69
clinical trials
Completed32 · 46%
Terminated11 · 16%
Withdrawn8 · 12%
Unknown status8 · 12%
Not yet recruiting4 · 6%
Active, not recruiting3 · 4%
Other3 · 4%
Clinical Trials
Trial Activity
69 trials
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03934840·22 enrolled
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
Enrolling by invitation·National Health Research Institutes, Taiwan·Phase 1/2·NCT05385861·52 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)